SOLOIST-WHF

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients with Type 2 Diabetes POST Worsening Heart Failure

Stadium
klaar
Middel
sotagliflozin
Populatie
Hartfalen
Fase
III
First Patient In
15 oktober 2018
Last Patient In
1 mei 2020
Last Patient Last Visit
19 mei 2020

National Lead

dr. J. Schaap

Cardioloog

De pagina is verlopen.